Table 4 Patients with improvement, no change, or decline in HRQoL based on minimal clinically important differences defined by an ECOG-based anchor
| Â | Â | Total FACT-MM; n (%) a | FACT-G; n (%) b | FACT-MM TOI; n (%) c | MM Domain; n (%) d | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Max N | Improvement | No change | Decline | Improvement | No change | Decline | Improvement | No change | Decline | Improvement | No change | Decline | |
Cycle 2 | 71 e | 9 (12.9) | 42 (60.0) | 19 (27.1) | 9 (12.9) | 38 (54.3) | 23 (32.9) | 10 (14.1) | 36 (50.7) | 25 (35.2) | 14 (19.7) | 39 (54.9) | 18 (25.4) |
Cycle 3 | 42 | 4 (9.5) | 25 (59.5) | 13 (31.0) | 4 (9.5) | 17 (40.5) | 21 (50.0) | 6 (14.3) | 22 (52.4) | 14 (33.3) | 9 (21.4) | 25 (59.5) | 8 (19.1) |
Cycle 4 | 25 | 2 (8.0) | 14 (56.0) | 9 (36.0) | 4 (16.0) | 10 (40.0) | 11 (44.0) | 1 (4.0) | 14 (56.0) | 10 (40.0) | 1 (4.0) | 17 (68.0) | 7 (28.0) |
Cycle 5 | 13 | 4 (30.8) | 3 (23.1) | 6 (46.2) | 4 (30.8) | 2 (15.4) | 7 (53.9) | 3 (23.1) | 2 (15.4) | 8 (61.5) | 1 (7.7) | 7 (53.9) | 5 (38.5) |
Cycle 6 | 8 f | 2 (28.6) | 2 (28.6) | 3 (42.9) | 2 (28.6) | 2 (28.6) | 3 (42.9) | 2 (28.6) | 2 (28.6) | 3 (42.9) | 2 (25.0) | 5 (62.5) | 1 (12.5) |
End of treatment | 38 | 3 (7.9) | 17 (44.7) | 18 (47.4) | 3 (7.9) | 11 (29.0) | 24 (63.2) | 3 (7.9) | 14 (36.8) | 21 (55.3) | 10 (25.6) | 13 (33.3) | 16 (41.0) |